# 法國將為重度肥胖患者報銷減重藥物費用。

*biotech · news · 2026-05-28 · Devdiscourse*

## Key points

- 法國將成為首個為重度肥胖患者報銷抗肥胖藥物費用的歐盟國家。
- 該計畫全面實施後，法國每年可能花費高達1億歐元。
- 法國社會保障將報銷65%的費用，但大多數符合資格的患者可獲得全額覆蓋。
- 覆蓋對象為BMI達35且有共病者，或BMI達40且無共病者。

France is set to become the first European Union nation to reimburse the cost of weight-loss drugs for severely obese patients, announced Health Minister Stephanie Rist. The medications, Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, have sparked a surge in anti-obesity treatment interest worldwide. Rist revealed the annual expense for the initiative could reach around €100 million ($116 million) at full deployment. French patients currently pay approximately €300 monthly for these medications. The program targets roughly one million individuals, but treatments will depend on individual cases and medical prescriptions. The reimbursement under France's social security system will cover the injectable treatments for those with a BMI of 35 plus a comorbidity or a BMI of 40 without any. Drugs will be covered at 65%, though most eligible patients receive full coverage. This move highlights France's proactive stance on public health issues, said Etienne Tichit of Novo Nordisk. (With inputs from agencies.)

**Companies:** Novo Nordisk, Eli Lilly
**Countries:** France

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3924625-frances-bold-move-state-coverage-for-breakthrough-obesity-drugs)

---

Canonical: https://newsio.io/zh-TW/n/a5db2d59-c4ba-4b97-8917-07e5728d3a47/wegovymounjaro
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works